Sjoerd J F Hermans, Yvette van Norden, Jurjen Versluis, Anita W Rijneveld, Bronno van der Holt, Okke de Weerdt, Bart J Biemond, Arjan A van de Loosdrecht, Lotte E van der Wagen, Mar Bellido, Michel van Gelder, Walter J F M van der Velden, Dominik Selleslag, Daniëlle van Lammeren-Venema, Vincent H J van der Velden, Liesbeth C de Wreede, Douwe Postmus, Francesco Pignatti, Jan J Cornelissen
BACKGROUND: We recently reported results of the prospective, open-label HOVON-100 trial in 334 adult patients with acute lymphoblastic leukemia (ALL) randomized to first-line treatment with or without clofarabine (CLO). No improvement of event-free survival (EFS) was observed, while a higher proportion of patients receiving CLO obtained minimal residual disease (MRD) negativity. AIM: In order to investigate the effects of CLO in more depth, two multi-state models were developed to identify why CLO did not show a long-term survival benefit despite more MRD-negativity...
May 2024: Cancer Medicine